Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 196

1.

A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations.

George SL, Izquierdo E, Campbell J, Koutroumanidou E, Proszek P, Jamal S, Hughes D, Yuan L, Marshall LV, Carceller F, Chisholm JC, Vaidya S, Mandeville H, Angelini P, Wasti A, Bexelius T, Thway K, Gatz SA, Clarke M, Al-Lazikani B, Barone G, Anderson J, Tweddle DA, Gonzalez D, Walker BA, Barton J, Depani S, Eze J, Ahmed SW, Moreno L, Pearson A, Shipley J, Jones C, Hargrave D, Jacques TS, Hubank M, Chesler L.

Eur J Cancer. 2019 Sep 11. pii: S0959-8049(19)30446-0. doi: 10.1016/j.ejca.2019.07.027. [Epub ahead of print]

2.

In vivo modelling of chemo-resistant neuroblastoma provides new insights into chemo-refractory disease and metastasis.

Yogev O, Almeida GS, Barker KT, George SL, Kwok C, Campbell J, Zarowiecki M, Kleftogiannis D, Smith LM, Hallsworth A, Berry P, Möcklinghoff T, Webber HT, Danielson LS, Buttery B, Calton EA, da Costa BM, Poon E, Jamin Y, Lise S, Veal GJ, Sebire N, Robinson SP, Anderson J, Chesler L.

Cancer Res. 2019 Aug 12. pii: canres.2759.2019. doi: 10.1158/0008-5472.CAN-18-2759. [Epub ahead of print]

PMID:
31405846
3.

Bias-adjusted Kaplan-Meier survival curves for marginal treatment effect in observational studies.

Wang X, Bai F, Pang H, George SL.

J Biopharm Stat. 2019;29(4):592-605. doi: 10.1080/10543406.2019.1633659. Epub 2019 Jul 9.

PMID:
31286838
4.

Auxiliary variable-enriched biomarker-stratified design.

Wang T, Wang X, Zhou H, Cai J, George SL.

Stat Med. 2018 Dec 30;37(30):4610-4635. doi: 10.1002/sim.7938. Epub 2018 Sep 16.

PMID:
30221368
5.

Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials.

Modjarrad K, Lin L, George SL, Stephenson KE, Eckels KH, De La Barrera RA, Jarman RG, Sondergaard E, Tennant J, Ansel JL, Mills K, Koren M, Robb ML, Barrett J, Thompson J, Kosel AE, Dawson P, Hale A, Tan CS, Walsh SR, Meyer KE, Brien J, Crowell TA, Blazevic A, Mosby K, Larocca RA, Abbink P, Boyd M, Bricault CA, Seaman MS, Basil A, Walsh M, Tonwe V, Hoft DF, Thomas SJ, Barouch DH, Michael NL.

Lancet. 2018 Feb 10;391(10120):563-571. doi: 10.1016/S0140-6736(17)33106-9. Epub 2017 Dec 5.

6.

On Enrichment Strategies for Biomarker Stratified Clinical Trials.

Wang X, Zhou J, Wang T, George SL.

J Biopharm Stat. 2018;28(2):292-308. doi: 10.1080/10543406.2017.1379532. Epub 2017 Oct 30.

7.

Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project.

Moreno L, Caron H, Geoerger B, Eggert A, Schleiermacher G, Brock P, Valteau-Couanet D, Chesler L, Schulte JH, De Preter K, Molenaar J, Schramm A, Eilers M, Van Maerken T, Johnsen JI, Garrett M, George SL, Tweddle DA, Kogner P, Berthold F, Koster J, Barone G, Tucker ER, Marshall L, Herold R, Sterba J, Norga K, Vassal G, Pearson AD.

Expert Opin Drug Discov. 2017 Aug;12(8):801-811. doi: 10.1080/17460441.2017.1340269. Epub 2017 Jun 26. Review.

PMID:
28604107
8.

Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.

Wang X, Wang X, Hodgson L, George SL, Sargent DJ, Foster NR, Ganti AK, Stinchcombe TE, Crawford J, Kratzke R, Adjei AA, Kindler HL, Vokes EE, Pang H.

Oncologist. 2017 Feb;22(2):189-198. doi: 10.1634/theoncologist.2016-0121. Epub 2017 Feb 10.

9.

Prevalence of data fraud.

George SL.

Int J Clin Oncol. 2016 Dec;21(6):1197. No abstract available.

PMID:
27255395
10.
11.

Time-dependent classification accuracy curve under marker-dependent sampling.

Zhu Z, Wang X, Saha-Chaudhuri P, Kosinski AS, George SL.

Biom J. 2016 Jul;58(4):974-92. doi: 10.1002/bimj.201500171. Epub 2016 Apr 27.

12.

Individualized 131I-mIBG therapy in the management of refractory and relapsed neuroblastoma.

George SL, Falzone N, Chittenden S, Kirk SJ, Lancaster D, Vaidya SJ, Mandeville H, Saran F, Pearson AD, Du Y, Meller ST, Denis-Bacelar AM, Flux GD.

Nucl Med Commun. 2016 May;37(5):466-72. doi: 10.1097/MNM.0000000000000470.

13.

Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from four CALGB (alliance) clinical trials.

Castillo JJ, Mulkey F, Geyer S, Kolitz JE, Blum W, Powell BL, George SL, Larson RA, Stone RM.

Am J Hematol. 2016 Feb;91(2):199-204. doi: 10.1002/ajh.24230. Epub 2015 Nov 26.

14.

Preclinical and clinical development of a dengue recombinant subunit vaccine.

Manoff SB, George SL, Bett AJ, Yelmene ML, Dhanasekaran G, Eggemeyer L, Sausser ML, Dubey SA, Casimiro DR, Clements DE, Martyak T, Pai V, Parks DE, Coller BA.

Vaccine. 2015 Dec 10;33(50):7126-34. doi: 10.1016/j.vaccine.2015.09.101. Epub 2015 Oct 14. Review.

PMID:
26458804
15.

Research misconduct and data fraud in clinical trials: prevalence and causal factors.

George SL.

Int J Clin Oncol. 2016 Feb;21(1):15-21. doi: 10.1007/s10147-015-0887-3. Epub 2015 Aug 20. Review.

PMID:
26289019
16.

CD8+ T-cell Responses in Flavivirus-Naive Individuals Following Immunization with a Live-Attenuated Tetravalent Dengue Vaccine Candidate.

Chu H, George SL, Stinchcomb DT, Osorio JE, Partidos CD.

J Infect Dis. 2015 Nov 15;212(10):1618-28. doi: 10.1093/infdis/jiv258. Epub 2015 May 5.

17.

Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial.

George SL, Wong MA, Dube TJ, Boroughs KL, Stovall JL, Luy BE, Haller AA, Osorio JE, Eggemeyer LM, Irby-Moore S, Frey SE, Huang CY, Stinchcomb DT.

J Infect Dis. 2015 Oct 1;212(7):1032-41. doi: 10.1093/infdis/jiv179. Epub 2015 Mar 19.

18.

Data fraud in clinical trials.

George SL, Buyse M.

Clin Investig (Lond). 2015;5(2):161-173.

19.

Mycobacterium ulcerans infection imported from Australia to Missouri, USA, 2012.

Thomas BS, Bailey TC, Bhatnagar J, Ritter JM, Emery BD, Jassim OW, Hornstra IK, George SL.

Emerg Infect Dis. 2014 Nov;20(11):1876-9. doi: 10.3201/eid2011.131534.

20.

Chikungunya update.

George SL.

Mo Med. 2014 Jul-Aug;111(4):343. No abstract available.

21.

Prospects for a dengue vaccine: progress and pitfalls.

George SL.

Mo Med. 2014 Jul-Aug;111(4):337-42.

22.

Human pegivirus (GB virus C) NS3 protease activity inhibits induction of the type I interferon response and is not inhibited by HCV NS3 protease inhibitors.

Chowdhury AY, Tavis JE, George SL.

Virology. 2014 May;456-457:300-9. doi: 10.1016/j.virol.2014.03.018. Epub 2014 Apr 24.

23.

Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808.

Kolitz JE, George SL, Benson DM Jr, Maharry K, Marcucci G, Vij R, Powell BL, Allen SL, Deangelo DJ, Shea TC, Stock W, Bakan CE, Hars V, Hoke E, Bloomfield CD, Caligiuri MA, Larson RA; Alliance for Clinical Trials in Oncology.

Cancer. 2014 Apr 1;120(7):1010-7. doi: 10.1002/cncr.28516. Epub 2013 Dec 31.

24.

Percutaneous cryoablation of renal tumours: outcomes from 171 tumours in 147 patients.

Breen DJ, Bryant TJ, Abbas A, Shepherd B, McGill N, Anderson JA, Lockyer RC, Hayes MC, George SL.

BJU Int. 2013 Oct;112(6):758-65. doi: 10.1111/bju.12122. Epub 2013 Apr 12.

25.

ROC curve estimation under test-result-dependent sampling.

Wang X, Ma J, George SL.

Biostatistics. 2013 Jan;14(1):160-72. doi: 10.1093/biostatistics/kxs020. Epub 2012 Jun 20.

26.

Gene selection using iterative feature elimination random forests for survival outcomes.

Pang H, George SL, Hui K, Tong T.

IEEE/ACM Trans Comput Biol Bioinform. 2012 Sep-Oct;9(5):1422-31.

27.

Docetaxel in the treatment of children with refractory or relapsed hepatoblastoma.

George SL, Broster S, Chisholm JC, Brock P.

J Pediatr Hematol Oncol. 2012 Oct;34(7):e295-7.

PMID:
22469940
28.

The GB virus C (GBV-C) NS3 serine protease inhibits HIV-1 replication in a CD4+ T lymphocyte cell line without decreasing HIV receptor expression.

George SL, Varmaz D, Tavis JE, Chowdhury A.

PLoS One. 2012;7(1):e30653. doi: 10.1371/journal.pone.0030653. Epub 2012 Jan 23.

29.

Higher antigen content improves the immune response to 2009 H1N1 influenza vaccine in HIV-infected adults: a randomized clinical trial.

El Sahly HM, Davis C, Kotloff K, Meier J, Winokur PL, Wald A, Johnston C, George SL, Brady RC, Lehmann C, Stokes-Riner A, Keitel WA.

J Infect Dis. 2012 Mar 1;205(5):703-12. doi: 10.1093/infdis/jir837. Epub 2012 Jan 24.

30.

Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission.

Farag SS, Maharry K, Zhang MJ, Pérez WS, George SL, Mrózek K, DiPersio J, Bunjes DW, Marcucci G, Baer MR, Cairo M, Copelan E, Cutler CS, Isola L, Lazarus HM, Litzow MR, Marks DI, Ringdén O, Rizzieri DA, Soiffer R, Larson RA, Tallman MS, Bloomfield CD, Weisdorf DJ; Acute Leukemia Committee of the Center for International Blood and Marrow Transplant Research and Cancer and Leukemia Group B.

Biol Blood Marrow Transplant. 2011 Dec;17(12):1796-803. doi: 10.1016/j.bbmt.2011.06.005. Epub 2011 Jun 21.

31.

Multiple testing for gene sets from microarray experiments.

Sohn I, Owzar K, Lim J, George SL, Mackey Cushman S, Jung SH.

BMC Bioinformatics. 2011 May 26;12:209. doi: 10.1186/1471-2105-12-209.

32.

Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia.

Buyse M, Squifflet P, Lange BJ, Alonzo TA, Larson RA, Kolitz JE, George SL, Bloomfield CD, Castaigne S, Chevret S, Blaise D, Maraninchi D, Lucchesi KJ, Burzykowski T.

Blood. 2011 Jun 30;117(26):7007-13. doi: 10.1182/blood-2011-02-337725. Epub 2011 Apr 25.

33.

Multiple testing of treatment-effect-modifying biomarkers in a randomized clinical trial with a survival endpoint.

Michiels S, Potthoff RF, George SL.

Stat Med. 2011 Jun 15;30(13):1502-18. doi: 10.1002/sim.4022. Epub 2011 Feb 23.

34.

Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720.

Baer MR, George SL, Sanford BL, Mrózek K, Kolitz JE, Moore JO, Stone RM, Powell BL, Caligiuri MA, Bloomfield CD, Larson RA; Cancer and Leukemia Group B.

Leukemia. 2011 May;25(5):800-7. doi: 10.1038/leu.2011.9. Epub 2011 Feb 15.

35.

Clinical trials data collection: when less is more.

Sargent DJ, George SL.

J Clin Oncol. 2010 Dec 1;28(34):5019-21. doi: 10.1200/JCO.2010.31.7024. Epub 2010 Oct 4. No abstract available.

PMID:
20921455
36.

Robust test method for time-course microarray experiments.

Sohn I, Owzar K, George SL, Kim S, Jung SH.

BMC Bioinformatics. 2010 Jul 22;11:391. doi: 10.1186/1471-2105-11-391.

37.

permGPU: Using graphics processing units in RNA microarray association studies.

Shterev ID, Jung SH, George SL, Owzar K.

BMC Bioinformatics. 2010 Jun 16;11:329. doi: 10.1186/1471-2105-11-329.

38.

P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808.

Kolitz JE, George SL, Marcucci G, Vij R, Powell BL, Allen SL, DeAngelo DJ, Shea TC, Stock W, Baer MR, Hars V, Maharry K, Hoke E, Vardiman JW, Bloomfield CD, Larson RA; Cancer and Leukemia Group B.

Blood. 2010 Sep 2;116(9):1413-21. doi: 10.1182/blood-2009-07-229492. Epub 2010 Jun 3.

39.
40.

A permutation-based multiple testing method for time-course microarray experiments.

Sohn I, Owzar K, George SL, Kim S, Jung SH.

BMC Bioinformatics. 2009 Oct 15;10:336. doi: 10.1186/1471-2105-10-336.

41.

Sample size calculation for microarray experiments with blocked one-way design.

Jung SH, Sohn I, George SL, Feng L, Leppert PC.

BMC Bioinformatics. 2009 May 28;10:164. doi: 10.1186/1471-2105-10-164.

42.

Between-arm comparisons in randomized Phase II trials.

Jung SH, George SL.

J Biopharm Stat. 2009;19(3):456-68. doi: 10.1080/10543400902802391.

43.

Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients.

George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM.

Hepatology. 2009 Mar;49(3):729-38. doi: 10.1002/hep.22694.

44.

Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery.

Demark-Wahnefried W, Polascik TJ, George SL, Switzer BR, Madden JF, Ruffin MT 4th, Snyder DC, Owzar K, Hars V, Albala DM, Walther PJ, Robertson CN, Moul JW, Dunn BK, Brenner D, Minasian L, Stella P, Vollmer RT.

Cancer Epidemiol Biomarkers Prev. 2008 Dec;17(12):3577-87. doi: 10.1158/1055-9965.EPI-08-0008.

45.

Tomorrow's cancer treatments today: the first 50 years of the Cancer and Leukemia Group B.

Green MR, George SL, Schilsky RL; Cancer and Leukemia Group B.

Semin Oncol. 2008 Oct;35(5):470-83. doi: 10.1053/j.seminoncol.2008.07.002. Review.

46.

Statistical challenges in preprocessing in microarray experiments in cancer.

Owzar K, Barry WT, Jung SH, Sohn I, George SL.

Clin Cancer Res. 2008 Oct 1;14(19):5959-66. doi: 10.1158/1078-0432.CCR-07-4532. Review.

47.

Statistical issues in translational cancer research.

George SL.

Clin Cancer Res. 2008 Oct 1;14(19):5954-8. doi: 10.1158/1078-0432.CCR-07-4537. Review.

48.

Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.

Baer MR, George SL, Caligiuri MA, Sanford BL, Bothun SM, Mrózek K, Kolitz JE, Powell BL, Moore JO, Stone RM, Anastasi J, Bloomfield CD, Larson RA.

J Clin Oncol. 2008 Oct 20;26(30):4934-9. doi: 10.1200/JCO.2008.17.0472. Epub 2008 Jun 30.

49.

Overcoming challenges in designing and implementing a phase II randomized controlled trial using a presurgical model to test a dietary intervention in prostate cancer.

Demark-Wahnefried W, George SL, Switzer BR, Snyder DC, Madden JF, Polascik TJ, Ruffin MT 4th, Vollmer RT.

Clin Trials. 2008;5(3):262-72. doi: 10.1177/1740774508091676.

50.

Randomized clinical trial design for assessing noninferiority when superiority is expected.

Freidlin B, Korn EL, George SL, Gray R.

J Clin Oncol. 2007 Nov 1;25(31):5019-23.

PMID:
17971602

Supplemental Content

Loading ...
Support Center